Outcomes in the treatment of aberrant subclavian arteries using the hybrid approach

Author:

Ben Ahmed Sabrina12ORCID,Settembre Nicla3,Touma Joseph4,Brouat Anthony5,Favre Jean-Pierre12,Jean Baptiste Elixene6,Chaufour Xavier7,Rosset Eugenio28,Malikov Serguei,Desgranges Pascal,Cochennec Fréderic,Favre Jean-Pierre,Hassen-Khodja Reda,Sadaghianloo Nirvana,Berger Ludovic,Maurel Blandine,Du Mont Lucie Salomon,Rinckenbach Simon,Bartoli Michel,Lermusiaux Patrick,Millon Antoine,Coscas Raphael,

Affiliation:

1. Service de Chirurgie Vasculaire et Cardiovasculaire, CHU Saint-Etienne , Saint-Etienne, France

2. Mines Saint-Etienne, Univ Lyon, Univ Jean Monnet, INSERM, U1059 Sainbiose, Centre CIS , Saint-Etienne, France

3. Service de Chirurgie Vasculaire, CHU Nancy, Université de Lorraine , Nancy, France

4. Service de Chirurgie Vasculaire, CHU Henri Mondor, AP-HP , Créteil, France

5. Service de Chirurgie Vasculaire, CHU Clermont-Ferrand , Clermont-Ferrand, France

6. Service de Chirurgie Vasculaire, CHU Nice , Nice, France

7. Service de Chirurgie Vasculaire, CHU Toulouse , Toulouse, France

8. Centre Cardio-Thoracique de Monaco , Monaco

Abstract

Abstract and keywords OBJECTIVES Aberrant subclavian artery (ASCA) occurs rarely but is one of the most frequent anatomical variations of the supra-aortic trunks. No consensus has been established on its best treatment. The goal of this study was to report the outcomes of ASCA treated by the hybrid approach. METHODS This non-interventional retrospective multicentre analysis included patients treated for ASCA by the hybrid approach in 12 French university hospitals between 2007 and 2019. The hybrid approach was defined as an endovascular procedure combined with open surgery or a hybrid stent graft. Patients were divided in 4 groups (from less to more complex treatment). The primary end point was 30-day mortality. The secondary end points were 30-day complications and late mortality. RESULTS This study included 43 patients. The mean age was 65 (SD, standard deviation: 16) years. Symptoms were found in 33 patients. Subclavian revascularization combined with aberrant subclavian artery occlusion was undertaken in 13 patients. Unilateral and bilateral subclavian revascularization combined with a thoracic aortic stent graft was undertaken in 11 and 6 patients, respectively. Total aortic arch repair combined with a thoracic aortic stent graft was undertaken in 13 patients. Thirty-day mortality was 2.3% with a technical success rate of 95.3%. The 30-day major postoperative complication rate was 16.3%: 4 strokes, 2 tamponades, 1 acute respiratory distress syndrome. Mean follow-up was 56.3 (SD: 44.7) months. The late mortality was 18.6%. CONCLUSIONS The ASCA hybrid approach is feasible, safe and effective with low early mortality. Morbidity is rather high. However, it increases with the complexity of the hybrid approach, which should be kept as simple as possible if the anatomical morphology allows.

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference24 articles.

1. Prevalence of the aberrant right subclavian artery reported in a published systematic review of cadaveric studies: the impact of an outlier;Polednak;Clin Anat,2017

2. Multi-detector computed tomography in the evaluation of variants and anomalies of aortic arch and its branching pattern;Rea;Ital J Anat Embryol,2014

3. Frequency and imaging findings of variations in human aortic arch anatomy based on multidetector computed tomography data;Celikyay;Clin Imaging,2013

4. Examen de quelques parties d’un singe;Hunauld F;Hist Acad Roy Sci,1735

5. Surgical Treatment for Dysphagia Lusoria;Gross;Ann Surg,1946

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3